Reproduction permitted for personal use only. For reprints and reprint permission, contact

Bone Care expands patent protection of core drug offering

Bone Care International, a Middleton-based University of Wisconsin spin-off, announced Tuesday that it had received a new patent on "stabilized hydroxyvitamin D" that will extend protection of its core druc, Hectorol.

The patent, which will expire in 2021, covers the company's hormone therapy treatment for hyperparathyroidism in chronic kidney disease patients, as well as the new version of Hectorol which Bone Care is currently working to complete.

Bone Care uses biotechnology developed at the UW to make drugs that treat the side effects of chronic kidney disease, such as the overactivity of the parathyroid glands. Founded in 1987 as a research and development firm, the company moved to Middleton in January 2001.

Aside from having its Hecterol capsules and injection treatments covered by the newly-issued patent, the company will continue to develop hormone therapies for a number of serious diseases, all based on the patented vitamin D complex.

Bone Care announced in May that the Massechusetts-based Genzyne Corp. agreed to acquire the company for $600 million in cash, a deal expected to be completed in the third quarter with shareholder approval. Genzyme has still not announced whether it will be keeping on Bone Care's current employees.

-Add Your Comment


Comment Policy: WTN News accepts comments that are on-topic and do not contain advertisements, profanity or personal attacks. Comments represent the views of the individuals who post them and do not necessarily represent the views of WTN Media or our partners, advertisers, or sources. Comments are moderated and are not immediately posted. Your email address will not be posted.

WTN Media cannot accept liability for the content of comments posted here or verify their accuracy. If you believe this comment section is being abused, contact

WTN Media Presents